Close Menu

NEW YORK – AstraZeneca and Merck on Thursday announced that their PARP inhibitor olaparib (Lynparza) was approved in the EU for two new indications: as a monotherapy for previously treated patients with metastatic, castration-resistant prostate cancer harboring BRCA1/2 mutations and as a maintenance treatment in combination with bevacizumab (Genentech's Avastin) for previously treated ovarian cancer patients with homologous recombination repair deficient (HRD) tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.